0000000001152801

AUTHOR

Adrián H. Teruel

showing 6 related works from this author

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

2019

[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water at an acidic and a neutral pH show negligible dye/drug release, yet a notable delivery took place when the reducing agent sodium dithionite is added because of hydrolysis of an azo bond in the capping ensemble. Additionally, olsalazine fragmentation induced 5-aminosalicylic acid (5-ASA) release. In vitro digestion models show that S1 and S2 solids are suitable systems to specifically release a pharmaceutical agent in the colon. In vivo pharmacokinetic studies in rats show …

MaleHydrocortisoneTECNOLOGIA DE ALIMENTOSReducing agentPharmaceutical Science02 engineering and technologyMesoporous silica microparticles030226 pharmacology & pharmacyInflammatory bowel diseaseSodium dithionite03 medical and health scienceschemistry.chemical_compoundHydrolysisDrug Delivery Systems0302 clinical medicineQUIMICA ORGANICAIn vivoDrug DiscoveryQUIMICA ANALITICAmedicineRhodamine BAnimalsGated materialsRats WistarMesalamineOlsalazineRhodaminesColon targeted releaseQUIMICA INORGANICAMesoporous silicaColitisInflammatory Bowel DiseasesSilicon Dioxide021001 nanoscience & nanotechnologySmart drug delivery materialsRatschemistryDrug deliveryMolecular Medicine0210 nano-technologymedicine.drugNuclear chemistry
researchProduct

Functional Magnetic Mesoporous Silica Microparticles Capped with an Azo-Derivative: A Promising Colon Drug Delivery Device

2018

[EN] Magnetic micro-sized mesoporous silica particles were used for the preparation of a gated material able to release an entrapped cargo in the presence of an azo-reducing agent and, to some extent, at acidic pH. The magnetic mesoporous microparticles were loaded with safranin O and the external surface was functionalized with an azo derivative 1 (bearing a carbamate linkage) yielding solid S1. Aqueous suspensions of S1 at pH 7.4 showed negligible safranin O release due to the presence of the bulky azo derivative attached onto the external surface of the inorganic scaffold. However, in the presence of sodium dithionite (azoreductive agent), a remarkable safranin O delivery was observed. A…

Pharmaceutical Science02 engineering and technologyFerric Compounds01 natural sciencesazo reductorcolon releaseAnalytical ChemistrySodium dithionitechemistry.chemical_compoundQUIMICA ORGANICADrug DiscoveryMoietymagnetic mesoporous silicaDrug CarriersAqueous solutionHydrolysisHydrogen-Ion ConcentrationSilicon Dioxide021001 nanoscience & nanotechnologyControlled releaseMicrospheresChemistry (miscellaneous)Drug deliveryMolecular Medicine0210 nano-technologyOxidation-ReductionPorosityColonSurface Properties010402 general chemistryArticleMagneticsChloridesSafraninQUIMICA ANALITICAHumansFerrous CompoundsPhysical and Theoretical Chemistrymagnetic mesoporous silica; azo derivatives; pH triggered; azo reductor; colon releaseQUIMICA INORGANICAOrganic ChemistryDithioniteMesoporous silica0104 chemical sciencesDrug LiberationchemistryNanoparticlesPhenazinespH triggeredMesoporous materialAzo Compoundsazo derivativesNuclear chemistryMolecules; Volume 23; Issue 2; Pages: 375
researchProduct

Efficacy of budesonide-loaded mesoporous silica microparticles capped with a bulky azo derivative in rats with TNBS-induced colitis.

2019

Abstract A colon targeted drug delivery system for inflammatory bowel diseases (IBD), consisting in budesonide loaded mesoporous silica microparticles functionalized with a selective azo-molecular gate (M-Bud), has been evaluated for in vivo efficacy. Experimental colitis in male Wistar rats was induced by rectal instillation of 2,4,6-trinitrobenzenesulfonic acid (TNBS). M-Bud was orally administered to the rats as a suspension in water. Colon/body weight ratio, clinical activity score, and histological evaluation were used as inflammatory indices to measure the performance of the microparticles. The formulation was compared with a suspension prepared from the commercial drug Entocord®. Sta…

DrugBudesonideMalemedia_common.quotation_subjectPharmaceutical Science02 engineering and technologyPharmacology030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicineDrug Delivery SystemsIn vivomedicineAnimalsColitisBudesonideTnbs colitismedia_commonChemistryMesoporous silica021001 nanoscience & nanotechnologymedicine.diseaseColitisSilicon DioxideControlled releasedigestive system diseasesRatsTargeted drug deliveryTrinitrobenzenesulfonic Acid0210 nano-technologyAzo Compoundsmedicine.drugInternational journal of pharmaceutics
researchProduct

New Insights of Oral Colonic Drug Delivery Systems for Inflammatory Bowel Disease Therapy

2020

[EN] Colonic Drug Delivery Systems (CDDS) are especially advantageous for local treatment of inflammatory bowel diseases (IBD). Site-targeted drug release allows to obtain a high drug concentration in injured tissues and less systemic adverse effects, as consequence of less/null drug absorption in small intestine. This review focused on the reported contributions in the last four years to improve the effectiveness of treatments of inflammatory bowel diseases. The work concludes that there has been an increase in the development of CDDS in which pH, specific enzymes, reactive oxygen species (ROS), or a combination of all of these triggers the release. These delivery systems demonstrated a th…

ColonAdministration OralReview02 engineering and technologyDiseaseIntestinal permeabilityInflammatory bowel diseasesPharmacology030226 pharmacology & pharmacyInflammatory bowel diseaseCatalysislcsh:ChemistryInorganic Chemistry03 medical and health sciencesDrug Delivery SystemsQUIMICA ORGANICA0302 clinical medicineIn vivoQUIMICA ANALITICAmedicineAnimalsHumansPhysical and Theoretical ChemistryMesalamineAdverse effectlcsh:QH301-705.5Molecular BiologySpectroscopyIntestinal permeabilitybusiness.industryQUIMICA INORGANICAOrganic ChemistryInflammatory Bowel DiseasesGeneral MedicineColitis021001 nanoscience & nanotechnologymedicine.diseaseSmall intestineComputer Science ApplicationsAminosalicylic AcidsDrug Liberationmedicine.anatomical_structurelcsh:Biology (General)lcsh:QD1-999Drug deliveryDrug delivery0210 nano-technologybusinessInternational Journal of Molecular Sciences
researchProduct

Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon.

2018

[EN] Mesoporous silica microparticles were prepared, loaded with the dye safranin O (M-Saf) or with the drug budesonide (M-Bud) and capped by the grafting of a bulky azo derivative. Cargo release from M-Saf at different pH values (mimicking those found in the gastrointestinal tract) in the absence or presence of sodium dithionite (a reducing agent mimicking azoreductase enzyme present in the colon) was tested. Negligible safranin O release was observed at pH 6.8 and 4.5, whereas a moderate delivery at pH 1.2 was noted and attributed to the hydrolysis of the urea bond that linked the azo derivative onto the external surface of the inorganic scaffold. Moreover, a marked release was observed w…

genetic structuresReducing agent02 engineering and technology010402 general chemistryMesoporous silica microparticlesColon targeting01 natural sciencesHigh-performance liquid chromatographyInflammatory bowel diseaseSodium dithionitechemistry.chemical_compoundHydrolysisQUIMICA ORGANICASafraninQUIMICA ANALITICAGated materialslcsh:ScienceBudesonideControlled drug releaseMultidisciplinaryQUIMICA INORGANICAMesoporous silica021001 nanoscience & nanotechnologyControlled release0104 chemical scienceschemistryUrealcsh:Q0210 nano-technologyNuclear chemistryRoyal Society open science
researchProduct

Supplementary Material from Mesoporous silica microparticles gated with a bulky azo derivative for the controlled release of dyes/drugs in colon

2018

Mesoporous silica microparticles were prepared, loaded with the dye safranin O (M-Saf) or with the drug budesonide (M-Bud) and capped by the grafting of a bulky azo derivative. Cargo release from M-Saf at different pH values (mimicking those found in the gastrointestinal tract (GIT)) in the absence or presence of sodium dithionite (a reducing agent mimicking azoreductase enzyme present in the colon) was tested. Negligible safranin O release was observed at pH 6.8 and 4.5, whereas a moderate delivery at pH 1.2 was noted and attributed to the hydrolysis of the urea bond that linked the azo derivative onto the external surface of the inorganic scaffold. Moreover, a marked release was observed …

researchProduct